|
|
Kumamoto University Repository System >
Research Center >
Center for AIDS Research >
Ｊｏｕｒｎａｌ Ａｒｔｉｃｅｌ （Center for AIDS Research） >
| |
|
|
| Title | : | Potent activity of a nucleoside reverse transcriptase inhibitor, 4′-ethynyl-2-fluoro-2′-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice |
| Authors | : | Hattori, Shinichiro
Ide, Kazuhiko
Nakata, Hirotomo
Harada, Hideki
Suzu, Shinya
Ashida, Noriyuki
Kogo, Satoru
Hayakawa, Hiroyuki
Mitsuya, Hiroaki
Okada, Seiji |
| Issue Date | : | Sep-2009 |
| Citation jtitle | : | Antimicrobial Agents and Chemotherapy |
| vol. | : | 53 |
| no. | : | 9 |
| start page | : | 3887 |
| end page | : | 3893 |
| Abstract | : | 4'-Ethynyl-2-fluoro-2'-deoxyadenosine(EFdA), a recently discovered nucleoside reverse transcriptase inhibitor (NRTI), exhibits a wide spectrum of wild-type and multi-drug-resistant clinical HIV-1 isolates (EC50: 0.0001–0.001μM). In the present study, we used human peripheral blood mononuclear cell (hu-PBMC)-transplanted human immunodeficiency virus type 1 (HIV)-infected, NOD/SCID, janus kinase-3-knock-out (NOJ) mice for in vivo evaluation of the anti-HIV activity of EFdA. Administration of EFdA decreased the replication and cytopathic effects of HIV-1 without identifiable adverse effects. In PBS-treated mice, the CD4+/ CD8+ cell ratio in the spleen was low (median: 0.04, range 0.02–0.49), while that in mice receiving EFdA was increased (median: 0.65, range 0.57–1.43). EFdA treatment significantly suppressed the number of HIV-1 RNA (median: 9.0×102 copies/ml, range: 8.1×102-1.1×103; versus 9.9×104 copies/ml, range: 8.1×102–1.1×103; P < 0.001) and p24 level in plasma (2.5×103 range: 8.2×102–5.6×103 pg/ml, versus 2.8×102 range: 8.2×101–6.3×102 pg/ml; p<0.001) and p24+ cells in the spleen (1.90 %, range: 0.33–3.68, versus median: 0.11 %, range: 0.00–1.00, p=0.003) in comparison with PBS-treated mice. These data suggest that EFdA is a promising candidate for a new age of HIV-1 chemotherapy and should be further developed as a potential therapy for individuals with multidrug-resistant HIV-1 variants. |
| URL | : | http://aac.asm.org/cgi/content/abstract/53/9/3887?ck=nck |
| Type Local | : | 雑誌掲載論文 |
| Publisher | : | American Society for Microbiology |
| Rights | : | © 2009, American Society for Microbiology. All Rights Reserved. |
| URI | : | http://hdl.handle.net/2298/12909 |
| Appears in Collections | : | Ｊｏｕｒｎａｌ Ａｒｔｉｃｅｌ （Center for AIDS Research）
|
|
|
Please use this identifier to cite or link to this item:
http://hdl.handle.net/2298/12909
|
|
HOME
